
<b>The studies show no consistent advantage for adjuvant chemotherapy in Uterine LMS.</b>
There is no increase in survival time.
  
Part of the problem is that most of the agents tried have low rates of response from LMS  tumors.  It will be interesting to see if a Gemcitabine clinical trial for grade I/II ULMS has better results.

Women whose tumors show invasion of blood vessels or lymphatic vessels are at greater risk of developing metastases.  At some centers, these women are offered AIM or other chemotherapy.  Again, the past clinical trials should be looked at, and the subject discussed carefully with the oncologists.

Search Pubmed for &&url
